Evidence map›Paper›PMID 40269991›Full record

ArticleBreast cancer research : BCR2025

Transfer learning drives automatic HER2 scoring on HE-stained WSIs for breast cancer: a multi-cohort study.

Xiaoping Li, Zhiquan Lin, Chaoran Qiu, Yiwen Zhang, Chuqian Lei, Shaofei Shen, Weibin Zhang, Chan Lai, Weiwen Li, Hui Huang and 1 more

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoping Li *Breast Department, Jiangmen Central Hospital, Jiangmen, China.
Zhiquan Lin *Hangzhou Dianzi University, Hangzhou, China.
Chaoran QiuBreast Department, Jiangmen Central Hospital, Jiangmen, China.
Yiwen ZhangBreast Department, Jiangmen Central Hospital, Jiangmen, China.
Chuqian LeiBreast Department, Jiangmen Central Hospital, Jiangmen, China.
Shaofei ShenShanxi Key Lab for Modernization of TCVM, College of Life Science, Shanxi Agricultural University, Taiyuan, 030000, Shanxi, China.
Weibin ZhangDepartment of Pathology, Jiangmen Central Hospital, Jiangmen, China.
Chan LaiRadiology Department, Jiangmen Central Hospital, Jiangmen, China.
Weiwen LiBreast Department, Jiangmen Central Hospital, Jiangmen, China.
Hui HuangDepartment of Breast Surgery, Jiangmen Maternity and Child Health Care Hospital, Jiangmen, 529000, Guangdong, China. feel709394@qq.com.
Tian QiuWuyi University, 99 Yinbin Avenue, Jiangmen, 529000, Guangdong, China. timeqiu@hotmail.com.

Funding

Guangdong Medical Science and Technology Research Fund Project No. B2023436Jiangmen Science and Technology Planning Project No. JZ202219National Natural Science Foundation of China No. 82372143Wu Jieping Medical Fund No.320.6750.2022-20-3
6 · The paper itself

Abstract

backgroundStreamlining the clinical procedure of human epidermal growth factor receptor 2 (HER2) examination is challenging. Previous studies neglected the intra-class variability within both HER2-positive and -negative groups and lacked multi-cohort validation. To address this deficiency, this study collected data from multiple cohorts to develop a robust model for HER2 scoring utilizing only Hematoxylin&Eosin-stained whole slide images (WSIs).

methodsA total of 578 WSIs were collected from five cohorts, including three public and two private datasets. Each WSI underwent adaptive scale cropping. The transfer-learning-based probabilistic aggregation (TL-PA) model and multi-instance learning (MIL)-based models were compared, both of which were trained on Cohort A and validated on Cohorts B-D. The model demonstrating superior performance was further evaluated in the neoadjuvant therapy (NAT) cohort. Scoring performance was assessed using the area under the receiver operating characteristic curve (AUC). Correlation between the model scores and specific grades (HER2 levels, pathological complete response (pCR) status, residual cancer burden (RCB) grades) were evaluated using Spearman rank correlation and Dunn's test. Patch analysis was performed with manually defined features.

resultsFor HER2 scoring, the TL-PA significantly outperformed the MIL-based models, achieving robust AUCs in four validation cohorts (Cohort A: 0.75, Cohort B: 0.75, Cohort C: 0.77, Cohort D: 0.77). Correlation analysis confirmed a moderate association between model scores and manual reader-defined HER2-IHC status (Coefficient

conclusionTL-PA shows robust generalization for HER2 scoring with minimal data; however, it still inadequately capture intra-class variability. This indicates that future deep-learning endeavors should incorporate more detailed annotations to better align the model's focus with the reasoning of pathologists.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorCohort StudiesEosine Yellowish-(YS)FemaleHematoxylinHumansMiddle AgedNeoadjuvant TherapyNeoplasm GradingROC CurveBiomarkers, TumorEosine Yellowish-(YS)ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHematoxylinBreast cancerHER2 scoringMulti-cohortTransfer learningWhole slide images

Identifiers

PMID40269991
PMCPMC12020254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.